OBJECTIVE: To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA). METHODS:Two hundred twelve patients with early RA (mean duration 1.5 years) were enrolled in a 24-week trial. Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 mg/day (n = 71), 800 mg/day (n = 71), and 1,200 mg/day (n = 66), followed by 18 weeks of open-label HCQ treatment at 400 mg/day. RESULTS: All patients had mild, active disease at the time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifying antirheumatic drugs; mean swollen joint count 8.6-10.4). Based on the Paulus criteria, response during the 6-week double-blind portion of the study was 47.97%, 57.7%, and 63.6% in the 400 mg/day, 800 mg/day, and 1,200 mg/day groups, respectively (P = 0.052). Discontinuations for adverse events were dose related (3 in the 400 mg/day group, 5 in the 800 mg/day group, 6 in the 1,200 mg/day group). Most involved the gastrointestinal (GI) system, with the background naproxen treatment possibly contributing. Ocular abnormalities occurred in 17 of 212 patients (8%) but were not dose related. CONCLUSION: Dose-loading with HCQ increased the degree of response at 6 weeks in this group of patients with early, predominantly seronegative RA. Adverse GI events were dose related, while adverse ocular events were not.
RCT Entities:
OBJECTIVE: To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA). METHODS: Two hundred twelve patients with early RA (mean duration 1.5 years) were enrolled in a 24-week trial. Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 mg/day (n = 71), 800 mg/day (n = 71), and 1,200 mg/day (n = 66), followed by 18 weeks of open-label HCQ treatment at 400 mg/day. RESULTS: All patients had mild, active disease at the time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifying antirheumatic drugs; mean swollen joint count 8.6-10.4). Based on the Paulus criteria, response during the 6-week double-blind portion of the study was 47.97%, 57.7%, and 63.6% in the 400 mg/day, 800 mg/day, and 1,200 mg/day groups, respectively (P = 0.052). Discontinuations for adverse events were dose related (3 in the 400 mg/day group, 5 in the 800 mg/day group, 6 in the 1,200 mg/day group). Most involved the gastrointestinal (GI) system, with the background naproxen treatment possibly contributing. Ocular abnormalities occurred in 17 of 212 patients (8%) but were not dose related. CONCLUSION: Dose-loading with HCQ increased the degree of response at 6 weeks in this group of patients with early, predominantly seronegative RA. Adverse GI events were dose related, while adverse ocular events were not.
Authors: Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Sarah B Goldberg; Jeffrey G Supko; Joel W Neal; Alona Muzikansky; Subba Digumarthy; Panos Fidias; Jennifer S Temel; Rebecca S Heist; Alice T Shaw; Patricia O McCarthy; Thomas J Lynch; Sreenath Sharma; Jeffrey E Settleman; Lecia V Sequist Journal: J Thorac Oncol Date: 2012-10 Impact factor: 15.609
Authors: Atiya R Faruqui; Denis Xavier; Sandhya K Kamat; Sujith J Chandy; Bikash Medhi; Raakhi K Tripathi; Yashashri C Shetty; John Michael Raj; Sandeep Kaushal; S Balakrishnan; Shubham Atal; Santanu K Tripathi; Dinesh K Badyal; Harihar Dikshit; Sukalyan Saha Roy; Niyati Trivedi; Suparna Chatterjee; Chetna Desai; C D Tripathi; Nirmala N Rege; Pooja Gupta; R Raveendran; Rajni Kaul; Nilima A Kshirsagar Journal: Indian J Med Res Date: 2021 Jan & Feb Impact factor: 2.375